Background: Hypertension-induced left ventricular hypertrophy (LVH) increases end-diastolic LV pressure and contributes to left atrial enlargement (LAE), which are associated with development of atrial fibrillation. However, the impact of LVH and LAE and their regression following antihypertensive therapy on atrial fibrillation incidence remains unclear. Methods: This retrospective analysis included consecutive patients with sinus rhythm who underwent echocardiography at hypertension diagnosis and after 6–18 months between 2006 and 2021 at tertiary care centres in Korea. LVH was defined as LV mass index greater than 115 g/m 2 (men) and greater than 95 g/m 2 (women), and LAE was defined as LA volume index greater than 42 ml/m 2 . The occurrence of new-onset atrial fibrillation (NOAF) was assessed in relation to changes in LVH and LAE status. Results: Among the 1464 patients included, 163 (11.1%) developed NOAF during a median 63.8 interquartile range (IQR) 35.9–128.5 months of surveillance period. New-onset LVH adjusted hazard ratio (aHR) 1.88, 95% confidence interval (CI) 1.20–2.94, P = 0.006 and LAE (aHR 1.89, 95% CI 1.05–3.40, P = 0.034) were significant predictors of NOAF. Conversely, regression of LVH (aHR 0.51, 95% CI 0.28–0.91, P = 0.022) or LAE (aHR 0.30, 95% CI 0.15–0.63, P = 0.001) was associated with a reduced risk for developing NOAF. Patients with both LVH and LAE at follow-up echocardiography had a higher risk for NOAF (aHR 4.30, 95% CI 2.81–6.56, P < 0.001) than those with either LVH or LAE or those with neither. Conclusion: The changes in left heart geometry can serve as a predictive marker for NOAF in patients with hypertension.
Kim et al. (Thu,) studied this question.